Cigna earnings beat by $0.04, revenue topped estimates
NEW YORK - SIGA Technologies, Inc. (NASDAQ:SIGA), a commercial-stage pharmaceutical company, declared on Tuesday a special cash dividend of $0.60 per share on its common stock, marking the fourth consecutive year for such a payout. The dividend, consistent with the previous year's amount, is scheduled to be paid on May 15, 2025, to shareholders of record as of April 29, 2025. According to InvestingPro data, while SIGA doesn't maintain a regular dividend policy, the company's strong financial position is evidenced by its impressive current ratio of 9.12 and minimal debt-to-equity ratio of 0.01.
The announcement reflects the company's strong financial position and its board's confidence in SIGA's future business prospects. Trading at a P/E ratio of 6.87 with a market capitalization of $380.76 million, InvestingPro analysis suggests SIGA is currently undervalued. "Today's announcement of a special cash dividend reflects the strength of our balance sheet and continued confidence in the future of our business," said Diem Nguyen, Chief Executive Officer of SIGA. She added that the company is focused on "disciplined financial management and strategic execution to drive long-term shareholder value." Get deeper insights into SIGA's valuation and 7 additional key ProTips with an InvestingPro subscription.
SIGA specializes in the development of novel treatments for infectious diseases, particularly those caused by orthopoxviruses. The company's flagship product, TPOXX® (tecovirimat), has been approved in the U.S. and Canada for the treatment of smallpox and has received authorization in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. InvestingPro data shows SIGA maintains a healthy gross profit margin of 68.57% and strong return on equity of 29%, though analysts anticipate some revenue decline in the current year.
While SIGA's press release contains forward-looking statements regarding future business development and plans, it also cautions that these statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks include potential delays or failures in product development, changes in government contracts, regulatory challenges, and the unpredictable nature of the biotechnology industry.
Investors are advised that the information in this article is based on a press release statement from SIGA Technologies, Inc.
In other recent news, SIGA Technologies Inc. reported its Q4 2024 earnings, showcasing a 2% growth in product sales, totaling $133 million for the year, with $81.4 million in revenue for the fourth quarter. The company maintains a strong cash position of $155 million and announced a special one-time cash dividend of $0.60 per share, set for distribution in May 2025. SIGA Technologies also appointed Retired U.S. Army General John "Jack" Keane to its Board of Directors, bringing expertise in national security and biodefense. General Keane's appointment includes stock options and an annual retainer. The company achieved a significant milestone with the regulatory approval of its antiviral TPOXX in Japan, further expanding its international presence. Additionally, SIGA Technologies continues to focus on delivering $70 million in outstanding orders in 2025. The company remains committed to its strategic initiatives, leveraging its strong financial position and regulatory successes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.